Press

1. IntelliDose Launches IntelliScribe March 2, 2010
2. IntrinsiQ Sharpens Cancer Treatment Analysis February 10, 2010
3. Dayton Physicians Commits to Clinical Excellence by Partnering with IntelliDose February 2, 2010
4. IntelliDose Exhibiting at Fifth Annual Community Oncology Conference February 5–6, 2010
5. New York cancer care center uses automation to handle coding, reimbursement January 29, 2010
6. Tarceva Reprieve? FDA Delay Could Mean Little Either Way January 25, 2010
7. WWMR Vice President Invited to Speak at PBIRG Fall Biotech Workshop December 7, 2009
8. Panel Advises on Clinical Pathways: What, Why, and How November, 2009
9. IntrinsiQ Expands Executive Team November 3, 2009
10. IntelliDose Exhibiting at North Carolina Oncology Management Society 2009 Fall Conference November 18 to 20, 2009
11. Opportunity reconsidered: maintenance therapy in oncology October, 2009
12. IntrinsiQ Study: Oncologists Overlook Maintenance Therapy Option – More Often than They Realize September 15, 2009
13. Industry Thought Leaders: A Discussion with Jeff Forringer, President of IntrinsiQ, LLC August 2009
14. Are CPOEs worth the investment? August 2009
15. Information Technology: Tracking the Evolution of Oncology Drug Prescribing August 2009
16. Rich Gray, General Manager of IntelliDose, to Speak at ACCC 26th National Oncology Economics Conference September 22 to 25, 2009
17. IntelliDose Exhibiting at eClinicalWorks 2009 National Users Conference September 12 to 15, 2009
18. Jeff Forringer, President of IntrinsiQ, to Speak at the Magellan/ICORE 6th Annual Oncology Summit September 11, 2009
19. IntelliDose Exhibiting at GE Centricity User Group Fall Conference August 28 and 29, 2009
20. How Much Should Cancer Drugs Cost: Landmark Cornell University Study Sheds New Light on Old Assumptions August 4, 2009
21. IntrinsiQ Sponsors Cancer Center Business Summit October 8-9, 2009
22. The First Step to a Paperless Practice July 1, 2009
23. On the Move – Spotlight on Jeff Forringer June 19, 2009
24. Specialized chemotherapies increase market share, cost of care June 2009
25. IntrinsiQ Acquires Market Research Firm WWMR June 9, 2009
26. IntrinsiQ Appoints New Executive Team May 12, 2009
27. IntrinsiQ's IntelliDose May 2009
28. The real cost of treating off-label and off-guidelines March 2009
29. NewsMakers March 2009
30. Small mistakes, huge consequences; Onc-specific software improves safety February 2009
31. Safe Handling; The Right Drug, Right Dose, Right Patient January/February 2009
32. Automated Oncology February 2009
33. Still Using Paper and Pen? January 2009
34. OnCare Hawaii Selects IntelliDose for Oncology Patient Safety and Practice Efficiency January 6, 2009
35. Safe Handling December 2008
36. Market Opportunity in Lung Cancer December 2008
37. Cancer Center of South Florida Selects IntelliDose for All-Electronic Practice November 3, 2008
38. IntrinsiQ Launches IntelliDose 3.8 October 27, 2008
39. Technology: Can Oncology EMRs Improve Quality? September 2008
40. IntrinsiQ Builds Out Its Oncology-Products Market Analytics September 2008
41. IntrinsiQ Wins 3 Top Honors from Inc. Magazine September 9, 2008
42. New Reporting from IntrinsiQ Measures Impact of Key Events on Oncology Drug Usage September 2, 2008
43. High Drug Costs a Factor in Cancer Care August 28, 2008
44. Pharmawire analysis: Cyclacel's seliciclib comes under physician scrutiny August 2008
45. DSS Licenses IntelliDose to Standardize VA Oncology Practices August 18, 2008
46. Buried Treasure June 23, 2008
47. Data from the Doctor April 15, 2008
48. IntrinsiQ LLC - Dose of Success March 7, 2008
49. IntelliCost Provides Cost of Therapy Insight for Sizing New Market Opportunities February 13, 2008
50. Software application aims to eliminate human error in chemotherapy dosing January 11, 2008
51. Oncologists Nationwide Choose IntelliDose for Clinical Safety and Efficiency November 28, 2007
52. IntrinsiQ Expands Oncology’s Gold-Standard for Patient Data Collection September 25, 2007
53. IntelliDose to Participate in ASCO EHR Symposium July 19, 2007
54. GE Healthcare and IntrinsiQ Announce Collaboration to Link Clinical Oncology Information within Patient Electronic Medical Records May 31, 2007
55. IntelliDose® Unveils IntelliCharge — Automated Encounter Charge Capture Improves Control and Billing of Costly Chemotherapy Drugs May 31, 2007
56. PRA International and IntrinsiQ Research Enter Exclusive Agreement for Oncology Patient Treatment Data March 19, 2007
57. Pulse and IntrinsiQ Sign Strategic Agreement January 16, 2007
58. IMS, IntrinsiQ Research Establish Strategic Alliance to Deliver Global, Clinically Rich Oncology Market Intelligence August 2, 2006
59. Accel-KKR Acquires Majority Stake in IntrinsiQ June 20, 2006

IntrinsiQ Acquires Market Research Firm WWMR

Adds Primary Research Capabilities, Tightly Aligned with Panel of 600+ Oncologists, to Reveal True Drivers behind Cancer Treatment Trends

Waltham, Mass. (June 9, 2009) — IntrinsiQ, the company improving the quality and understanding of cancer care, today announced the acquisition of market research and consulting firm WWMR, Inc. The combination creates the single, go-to source for pharmaceutical companies seeking to understand the true drivers behind physicians' cancer treatment decisions to navigate today's fast-moving, high-stakes medical oncology market.

Through this acquisition, IntrinsiQ now offers a complete suite of primary and secondary oncology market research capabilities to provide validated insight into how oncologists perceive treatment standards – and how they actually practice medicine. For the first time, primary research panels can be quickly assembled and tightly aligned with IntrinsiQ's real-time database of more than 600 oncologists nationwide and their practice behavior.

Founded 15 years ago, WWMR brings deep expertise in oncology research having established and served as the secondary market research arm of Genentech for the past decade. The boutique firm specializes in qualitative and quantitative market research, product and market assessments, forecasts, and economic analysis conducted through every stage of the clinical research and drug development process.

"As oncology treatment becomes more complex and more specialized, the stakes get raised on pharmaceutical teams' sizeable R&D investment," said Mike Raquet, general manager of IntrinsiQ's pharmaceutical information division. "WWMR brings deep understanding and immediate access to doctors on the front lines – the best way for pharmaceutical companies to affirm strategic directions sooner, and with greater assurances for ROI."

Twenty-seven of the top 30 pharmaceutical oncology organizations rely on IntrinsiQ's unmatched database of 2 million drug administrations given annually, collected from oncology practices nationwide using IntrinsiQ's flagship clinical oncology software, IntelliDose®.

"This alignment is a perfect marriage because of our organizations' shared mission of improving the quality and understanding of cancer care," said Susan Olsen, WWMR founder and president, who becomes vice president, consulting services in IntrinsiQ's pharmaceutical information division. "IntrinsiQ has long been the gold standard in oncology data, and we're thrilled to join their team."

WWMR will retain its name and maintain offices in San Mateo, California. All WWMR employees will join IntrinsiQ. The firm also will continue to offer its custom consulting and market research services in non-oncology markets, including patient panels in chronic pain, cardiology and cystic fibrosis, as well as its Neuropathic, Cancer, and Back Pain reports.

About IntrinsiQ

IntrinsiQ, LLC is the leading provider of medical oncology clinical information systems and the premier source of US oncology data and analysis. Each month, IntrinsiQ's clinical software application, IntelliDose®, captures the treatment decisions and details from more than 500 oncologists, for nearly 20,000 unique patients, creating a database unrivaled in accuracy, detail and timeliness of information about the medical oncology care process. This database is the foundation of products and services that uniquely address the business information needs of pharmaceutical product managers, market researchers and financial analysts. For more information, please visit www.intrinsiq.com.

About WMMR

WWMR is a marketing research and strategic consulting firm founded in 1994, providing insightful, proprietary studies to pharmaceutical, biotech, medical device, and diagnostics companies worldwide. Using primary and secondary research methodologies, WWMR provides insights on current and emerging markets using their expertise in product and technology assessments, forecast modeling, epidemiology projections, product launch monitoring (pre- and post-), primary marketing research and medical economic analyses. For more information, visit www.wmmr.com.

IntrinsiQ Company Contact:

Diane Poth
(781) 434-3304
diane.poth@intrinsiq.com

IntrinsiQ Media Contact:

Lesley Cannata
(617) 969-9192
lcannata@corporateink.com

© 2010 IntrinsiQ, LLC